ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1347	National Cancer Institute	Html	null	Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of pancreatic neuroendocrine tumors (islet cell tumors).			CLICK HERE
1352	National Cancer Institute	Html	en	Bladder Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of bladder cancer.	bladder infections 0.409188 cancer spreads 0.362526 body 0.421643 type 0.363946 transitional cell carcinoma 0.368057 Partial cystectomy 0.367914 following PDQ summaries 0.361033 PDQ cancer information 0.437047 cancer increases 0.35829 clinical trial search 0.428286 bladder cancer 0.996648 clinical trials 0.716737 stage IV bladder 0.400568 cancer information summary 0.412718 clinical trial 0.562865 Institute about bladder 0.388854 breast cancer prevention 0.364729 superficial bladder cancer 0.471082 patients 0.385176 treatment clinical trial 0.370642 PDQ Adult Treatment 0.359776 NCI PDQ cancer 0.382156 lymph nodes 0.358627 radiation therapy 0.477016 Treatment Editorial Board 0.366853	metastatic bladder cancer 0.451959 General information 0.370997 general cancer information 0.374576 treatment 0.542299 cancer prevention 0.364857 new cancer treatments 0.373348 Recurrent bladder cancer 0.48553 NCI-supported cancer 0.389073 Cancer Information Service 0.375145 urinary diversion 0.368656 invasive bladder cancer 0.467339 treatment clinical trials 0.395244 National Cancer Institute 0.448421 radical cystectomy 0.396674 new treatment 0.433088 External radiation therapy 0.441508 Bladder Cancer Treatment 0.456321 Cancer Care page 0.36454 Blood. The cancer 0.364373 bladder cancer cells 0.466875 cancer research process 0.367381 cancer clinical trials 0.446025 cancer information summaries 0.373713 comprehensive cancer information 0.373405	CLICK HERE
1381	National Cancer Institute	Html	en	Skin Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing skin cancer and about research aimed at the prevention of this disease.	skin cancer 0.822138 NMSC lesion reduction 0.586326 skin cancer reduction 0.555393 self-reported midday sun 0.540371 average new lesions 0.584312 Skin Cancer Prevention 0.571287 study attrition rates 0.542607 new actinic keratoses 0.584773 fewer actinic lesions 0.603501 skin cancer—a time 0.536376 daily sunscreen application 0.747804 poor surrogate endpoint 0.539998 6-month post-intervention follow-up 0.542973 fewer new lesions 0.602501 solar keratoses 0.994656 provider-based sun protection 0.532584 sun protection factor 0.548485 Australian randomized study 0.58712 regular sunscreen 0.624027 sunscreen placebo 0.612947 UV radiation exposure 0.5401 clinically normal skin. 0.54962 SCC prevention trials 0.561668	new solar keratoses 0.591696 sun-protective behaviors 0.556779 significantly lower number 0.53979 chemopreventive agent 0.53119 invasive skin cancer 0.584968 community skin cancer 0.550184 population-based longitudinal study 0.568978 significantly greater number 0.537464 placebo group 0.679758 NMSC incidence rates 0.595744 Reduce Actinic Cancer 0.56707 spontaneous regression rate 0.544682 4-month clinical trials 0.540996 randomized controlled trial 0.576053 new lesions 0.702948 randomized trials 0.539994 nicotinamide group 0.630321 base-cream placebo group 0.599568 appearance-based behavioral interventions 0.531285 sun exposure 0.594318 sunscreen group 0.779335 NMSC lesions 0.609075 self-reported sun-protective behaviors 0.541953	CLICK HERE
1592	National Cancer Institute	Html	en	Thymoma and Thymic Carcinoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of thymoma and thymic carcinoma.	cancer treatment 0.359999 malignant tumor cells 0.342024 body 0.355156 type 0.305883 PDQ cancer information 0.433839 clinical trial search 0.425022 cancer cell 0.325256 thymic carcinoma cells 0.326827 clinical trials 0.988832 thymoma 0.371455 cancer information summary 0.383363 clinical trial 0.804071 patients 0.340124 earlier clinical trials 0.306378 thymic carcinoma spreads 0.306453 treatment clinical trial 0.327343 PDQ Adult Treatment 0.30754 NCI PDQ cancer 0.333099 radiation therapy 0.826788 Treatment Editorial Board 0.331284 thymic carcinomas 0.308782 General information 0.310597 general cancer information 0.312288 thymic carcinoma 0.970766 treatment 0.610928	new ways 0.369751 anticancer drugs 0.338472 new cancer treatments 0.318168 NCI-supported cancer 0.344007 cancer cells 0.453663 Cancer Information Service 0.312701 treatment clinical trials 0.363023 thymic carcinoma look 0.319623 National Cancer Institute 0.457133 tumor cells 0.34225 normal cells 0.313543 new treatment 0.393453 new combinations 0.333745 Blood. The cancer 0.306577 metastatic tumor 0.308755 PDQ summary 0.316304 cancer clinical trials 0.447345 stage 0.3338 tumor 0.364487 cancer information summaries 0.310618 comprehensive cancer information 0.311036 Thymic Carcinoma Treatment 0.323064 cancer 0.980046 standard treatment 0.319507	CLICK HERE
1690	National Cancer Institute	Html	en	Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of pheochromocytoma and paraganglioma.	cancer treatment 0.520384 malignant tumor cells 0.51392 inherited pheochromocytoma 0.499674 metastatic pheochromocytoma 0.559666 catecholamine levels 0.546812 recurrent pheochromocytoma 0.523941 body 0.55921 PDQ cancer information 0.583541 clinical trial search 0.545652 clinical trials 0.955841 adrenal gland 0.817016 cancer information summary 0.547255 clinical trial 0.684878 blood pressure 0.689096 entire adrenal gland 0.501423 detailed pictures 0.500985 patients 0.570303 pheochromocytoma 0.843137 blood vessels 0.513601 PDQ Pheochromocytoma 0.514265 NCI PDQ cancer 0.498564 lymph nodes 0.51055 radiation therapy 0.504762 tyrosine kinase inhibitor 0.539116	benign pheochromocytoma 0.496121 treatment 0.708415 general information 0.506946 magnetic resonance imaging 0.497402 cancer cells 0.57041 adrenal cortex 0.501382 adrenal medulla 0.501576 multiple endocrine neoplasia 0.503339 treatment clinical trials 0.532049 National Cancer Institute 0.548616 tumor cells 0.524483 new treatment 0.564593 heart rate 0.509798 pheochromocytoma spreads 0.501294 pheochromocytoma cells 0.532172 Pheochromocytoma forms 0.519073 adrenal glands 0.85433 nuclear magnetic resonance 0.499251 paraganglioma 0.578972 tumors 0.523973 cancer clinical trials 0.561663 high blood pressure 0.675166 tumor 0.650897 cancer 0.88724	CLICK HERE
1940	National Cancer Institute	Html	es	La espiritualidad en el tratamiento del cáncer (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de la influencia que tiene la espiritualidad y la religión en las personas que tienen cáncer. Se discuten varios métodos sobre manejo e intervención.	enfermos ayuda 0.452293 La espiritualidad 0.924579 términos espiritualidad 0.486044 siguientes aspectos 0.444194 Physician Data Query 0.534722	National Cancer Institute 0.427034 siguientes riesgos 0.41834 libre uso 0.416111 siguientes maneras 0.524006 Instituto Nacional 0.45946	CLICK HERE
2073	National Cancer Institute	Html	es	Biopsia de ganglio linfático centinela	Describe el procedimiento de biopsia de ganglio linfático centinela, su uso para determinar la extensión, o estadio, del cáncer en el cuerpo, y los resultados de investigación sobre el uso de este tipo de biopsia en cáncer de seno y melanoma.	Surgical Adjuvant Breast 0.600625 Lancet Oncology 0.600394 falsa sensación 0.600322 American Medical Association 0.600457 Hunt KK 0.600275 excelente resultado 0.600374 Anderson SJ 0.600281 ganglio linfático centinela 0.999164 Selective Lymphadenectomy Trial 0.600594 Bowel Project 0.600314 células inmunitarias llamadas 0.601282 Julian TB 0.600295 Ballman KV 0.60032 linfocitos b 0.600438 Giuliano AE 0.600304 rara vez 0.60032 ganglios linfáticos centinelas 0.613287 sentinel node metastasis 0.600629 axillary dissection 0.600834 Instituto Nacional 0.602213	Krag DN 0.600307 Lyman GH 0.600292 Axillary dissection vs 0.600551 fase iii 0.601556 Surgeons Oncology Group 0.600619 ganglio centinela 0.636993 ecografía rutinaria 0.600317 pequeña incisión 0.600338 overall survival findings 0.600577 PubMed Abstract 0.601839 sentinel lymph 0.601172 Silbermins D 0.600275 with invasive breast 0.600626 Lymphatic mapping 0.600313 patients with 0.600887 linfadenectomía axilar 0.605014 Instituto Oncológico John 0.60052 Clinical Oncology 0.600393 NSABP B-32 0.600293	CLICK HERE
3712	National Cancer Institute	Html	en	Understanding Precision Medicine in Cancer Treatment	Precision medicine helps doctors select cancer treatments that are most likely to help patients based on a genetic understanding of their disease. Learn about the promise of precision medicine and the role it plays in cancer treatment.	cancer treatment 0.440203 routine care 0.360336 tumor profiling 0.359671 medicine clinical trials 0.414587 type 0.382285 specific change 0.357217 new treatments 0.362099 treatments 0.484331 research 0.393932 open trials 0.357639 rectal cancers 0.362107 Targeted Cancer Therapies 0.436947 clinical trials 0.515013 cancer-causing genetic changes 0.439486 precision medicine approach 0.418811 additional genetic changes 0.428246 cancer-causing changes 0.378722 researchers 0.363172 patients 0.398147 trial staff 0.356601 cancer types 0.375159 patient care 0.366351 different types 0.361116 Tumor DNA Sequencing 0.40382 radiation therapy 0.360769	precision medicine 0.96121 person’s cancer 0.378533 genetic tests 0.37503 treatment 0.491183 precision medicine trials 0.417382 United States 0.359831 Cancer Information Service 0.419259 special lab 0.36045 targeted drug 0.368994 genetic understanding 0.381915 consent form 0.358985 different people 0.367337 Research studies 0.361413 molecular profiling 0.357183 drugs 0.382294 specific genetic changes 0.430567 certain genetic changes 0.427035 Targeted Therapy 0.372422 recent advances 0.370536 genetic changes 0.967087 specific types 0.356978 medicine clinical trial 0.490589 search tool 0.359567 cancer 0.783975	CLICK HERE
16567	National Cancer Institute	Html	en	Pembrolizumab Improves Survival for Some Patients with Advanced Non-Small Cell Lung Cancer	A summary of clinical trial results showing that pembrolizumab improved progression-free and overall survival for patients with advanced non-small cell lung cancer.	platinum-based chemotherapy 0.628936 PD-L1 positive tumors 0.620887 advanced non-small cell 0.629259 PD-L1 expression 0.628117 1-year overall survival 0.61848 higher progression-free survival 0.617259 chemotherapy 0.698592 time patients 0.588415 chemotherapy group 0.668963 immune-mediated adverse events 0.635601 Dana-Farber Cancer Institute 0.607312 lung cancer 0.570765 biomarker. Earlier trials 0.611797 PD-L1 IHC 22C3 0.643265 immune response 0.572023 PD-L1 protein present 0.63991 overall survival 0.629887 immune-mediated deaths 0.578857 National Cancer Institute 0.604313 tumor cells 0.913581 randomized phase 0.574689 median progression-free survival 0.633329 PD-L1-expressing tumor cells 0.661448 immune therapy 0.577956	immune-mediated events 0.578589 progression-free survival 0.757999 pembrolizumab group 0.672943 platinum-based doublet chemotherapy 0.672126 standard chemotherapy 0.609699 phase III CheckMate 0.569846 patients 0.63251 trial results 0.620704 previously treated patients 0.61738 immune cells 0.61252 adverse events 0.670445 Dr. Malik 0.709776 earlier phase trial 0.627214 metastatic NSCLC 0.599852 Bruce E. Johnson 0.59961 survival advantage 0.568599 untreated advanced NSCLC 0.642891 New England Journal 0.615224 severe skin reactions 0.605442 checkpoint inhibitor pembrolizumab 0.658193 phase III trial 0.569107 Pembrolizumab blocks PD-1 0.629649 Shakun Malik 0.582607	CLICK HERE
16837	National Cancer Institute	Html	en	Stanford University — Cancer Translational Nanotechnology Training Program	The focus of the Stanford University Cancer Nanotechnology Training Center is presented here.	interdisciplinary leaders 0.696815 program director 0.689314 nanoengineering 0.558309 M.D. 0.531791 molecular imaging 0.829201 faculty 0.529401 3-year program 0.755923 proposed 5-year cycle 0.860016 Ph.D. 0.531868 skill sets 0.677497 trainee progress 0.671123 Stanford Cancer-Translational Nanotechnology 0.898203 cancer immunology 0.705615 molecular pharmacology 0.687504 gene therapy 0.664625 cross-disciplinary training 0.726482 complementary mentors 0.683687 coursework 0.53863 biochips 0.551532 Stanford CNTC website 0.833637 interdisciplinary researchers 0.692233 molecular biology 0.695814 Jianghong Rao 0.719515 electrical engineering 0.669775	grant application process 0.806404 cancer research 0.843254 research advisor 0.68327 Advisory Committee 0.662141 Stanford Oncology Clinical 0.845549 National Cancer Institute 0.835301 Principal Investigator 0.706879 postdoctoral trainees 0.850619 Dean Felsher 0.699264 Training Committee 0.688222 clinical translation 0.702935 materials science 0.66948 nanomedicine 0.549348 3-year training program 0.964337 hands-on training activities 0.833884 clinical component 0.680058 bioengineering 0.539755 cancer nanotechnology translation 0.891967 Lecture Series 0.660584 clinical cancer medicine 0.877908 entire program 0.674038 Training Focus 0.735031 cancer biology 0.706458 mock grant proposal 0.812529	CLICK HERE